Navigation Links
Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013

ANAHEIM, Calif., Feb. 6, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced that it will release fourth quarter and full year 2012 financial results on Tuesday, February 26, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, February 26, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter and full year, as well as current corporate developments.

The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website,
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.  The telephone dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 95427085.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications:  the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, the treatment of infantile spasms in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.    For more information about Questcor, please visit


SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
2. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
3. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
4. Questcor to Conduct Conference Call to Discuss Reimbursement Process
5. Questcor Comments on Insurance Policy Bulletin
6. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
7. Questcor Pharmaceuticals to Present at Investor Conferences in September
8. Questcor Reports Second Quarter Financial Results
9. Questcor to Report Second Quarter Results on July 24, 2012
10. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
11. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
Post Your Comments:
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
(Date:11/26/2015)... and Markets ( ) has announced the addition of ... - Rise in Cardiac Disorders and Growing Awareness among People ... Boston scientific and others. ... others. --> The market is dominated by ... scientific and others. Asia ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
(Date:11/26/2015)... ... , ... Inevitably when people think Thanksgiving, they also think Holiday sales and ... Friday and Cyber Monday massage chair sales to receive the best pricing ... to find the best massage chair deals, they can see all of the coupons ...
Breaking Medicine News(10 mins):